RT Journal Article
T1 In vitro evaluation of graphene oxide nanosheets on immune function
A1 Feito Castellano, María José
A1 Vila, Mercedes
A1 Matesanz Sancho, Mª Concepción
A1 Linares, J.
A1 Gonçalves, G.
A1 Marques, P.A.A.P.
A1 Vallet Regí, María Dulce Nombre
A1 Rojo, J.M.
A1 Portolés Pérez, María Teresa
AB Graphene oxide (GO) has attracted the scientific community attention due to its novel properties and wide range of potential applications including hyperthermia cancer therapy. However, little is known about the GO effects on the immune function which involves both innate and adaptive defence mechanisms through the activation of different cell populations and secretion of several cytokines. The effect of different GO nanosheets designed for hyperthermia cancer therapy on macrophage and lymphocyte function should be determined before using GO for this application. Experiments The effects of GO nanosheets with 1 (1-GOs) and 6 arms (6-GOs) of polyethylene glycol on RAW-264.7 macrophages and primary splenocytes (as approximation to the in vivo situation) were evaluated through the proinflammatory cytokine secretion and the modulation of cell proliferation in the presence of specific stimuli for either T-lymphocytes (concanavalin A, anti-CD3 antibody) or B-lymphocytes/macrophages (lipopolysaccharide). Findings 6-GOs significantly increased the secretion of TNF-α by RAW-264.7 macrophages without alteration of IL-6 and IL-1β levels. The treatment of primary splenocytes with 1-GOs and 6-GOs in the presence of concanavalin A, anti-CD3 antibody and lipopolysaccharide, produced significant dose-dependent decreases of cell proliferation and IL-6 levels, revealing weak inflammatory properties of GOs which are favourable for hyperthermia cancer therapy.
PB Elsevier
SN 0021-9797
YR 2014
FD 2014
LK https://hdl.handle.net/20.500.14352/34726
UL https://hdl.handle.net/20.500.14352/34726
LA eng
NO Comunidad de Madrid
NO CICYT
NO Ministerio de Ciencia e Innovación (MICINN)
NO Ministerio de Economía y Competitividad (MINECO)
NO CIBER-BBN
NO Fundação para a Ciência e Tecnologia
DS Docta Complutense
RD 9 abr 2025